Recombinant Human Killer cell immunoglobulin-like receptor 2DL2 (KIR2DL2)

What is the genetic relationship between KIR2DL2 and KIR2DL3?

KIR2DL2 and KIR2DL3 have historically been given different names based on their cDNA sequences, but genome analysis and population studies indicate they may be alleles at the same locus. They share high homology in their structures and binding properties, though with different binding affinities. Genome studies demonstrate that these receptors appear on the same genetic locus but have evolved into distinct allelic variants with functional differences in their interactions with HLA-C ligands . This genetic relationship explains why individuals can have either KIR2DL2, KIR2DL3, or both in their genotype.

How does KIR2DL2 function in regulating NK cell activity?

KIR2DL2 functions primarily as an inhibitory receptor on Natural Killer cells, regulating immune responses by dampening NK cell activation when engaged with appropriate HLA-C ligands. When KIR2DL2 binds to its cognate ligands (primarily HLA-C1 group molecules), it delivers inhibitory signals that prevent NK cell degranulation and cytokine production. This inhibitory function is physiologically important for self-tolerance but can be exploited by pathogens. KIR2DL2 combines more strongly with HLA-C than KIR2DL3, potentially exerting a more powerful inhibitory effect that may promote survival of viruses by preventing early clearance . KIR expression on NK cells is largely random, creating diverse NK cell subpopulations with varying receptor combinations and functional capacities .

What are the primary HLA-C ligands for KIR2DL2 and how specific is this interaction?

While traditionally KIR2DL2 was thought to specifically recognize HLA-C molecules of the C1 group, research has revealed a broader spectrum of interaction. According to recent findings, KIR2DL2+ NK cells react similarly against HLA-C+ target cells regardless of whether they express C1 or C2 alleles . This contrasts with KIR2DL1, which shows strict specificity for C2 alleles. The research demonstrates that KIR2DL2 has a weaker affinity for C2 ligands with the N77K80 motif, but still maintains reactivity . This broader specificity may partially explain the predominance of KIR2DL2-expressing NK cells within the KIR repertoire in KIR2DL2-positive individuals.

How does KIR2DL2 expression impact susceptibility to COVID-19?

Research indicates that KIR2DL2 gene frequency is significantly higher in COVID-19 patients compared to healthy controls, suggesting a predisposition to infection. A study found a positive correlation between KIR2DL2 frequency in populations and the number of COVID-19 cases in specific geographic regions . The KIR2DL2/HLA-C1C1 pairing appeared more frequently in COVID-19 patients than in healthy individuals, suggesting people carrying this gene-ligand combination may be at higher risk for COVID-19. The inhibitory action of KIR2DL2 on NK cell activation likely prevents early clearance of SARS-CoV-2, allowing the virus to establish infection . Importantly, the protective effect of KIR2DL3/HLA-C1 pairing was found to be dependent on the absence of KIR2DL2, further emphasizing KIR2DL2's role in COVID-19 susceptibility.

What is known about KIR2DL2's role in herpesvirus infections and reactivation?

KIR2DL2 expression increases susceptibility to herpesvirus infections, particularly in patients with certain conditions like multiple sclerosis (MS). Studies have shown that MS patients expressing KIR2DL2 on NK cells demonstrate increased susceptibility to human herpesvirus (HHV) infections, especially EBV and HHV-6 . The receptor/ligand pair KIR2DL2/HLA-C1 has been identified as a predisposing factor for HSV-1 infection and reactivation. In MS patients, NK cells expressing KIR2DL2 show reduced activation against HHV infection compared to control subjects . Studies reported the highest HHV-6 viral load in MS patients with KIR2DL2 expression, accompanied by increased percentages of subjects positive for IgG against HHV-6 in KIR2DL2-positive MS patients compared to controls . This suggests that KIR2DL2 plays a significant role in controlling herpesvirus latency and reactivation.

How does KIR2DL2 affect HCV infection outcomes?

KIR2DL2 has been associated with both HCV infection rates and viral clearance. Previous research has found that the presence of KIR2DL2 inhibits the NK cell response to HCV-infected patients in the Chinese Han population . As KIR2DL2 combines more strongly with HLA-C than KIR2DL3, it may exert a more powerful inhibitory effect on NK cells that promotes survival of the virus. The stronger inhibitory signal from KIR2DL2 likely compromises the ability of NK cells to efficiently eliminate HCV-infected hepatocytes during early infection. This reduced early antiviral response allows the virus to establish a foothold in the host, potentially leading to chronic infection . The relationship between KIR2DL2 and HCV underscores the critical role of NK cell inhibitory receptors in determining viral infection outcomes.

What is the relationship between KIR2DL2 and multiple sclerosis?

Research has established a connection between KIR2DL2 expression and increased susceptibility to multiple sclerosis (MS), particularly in relation to viral infections. Studies show that MS patients expressing KIR2DL2 on NK cells demonstrate greater susceptibility to human herpesvirus (HHV) infections, especially EBV and HHV-6 . The mechanism appears to involve decreased NK cell activation against viral infections in KIR2DL2-positive MS patients, whereas control subjects with KIR2DL2 show no such deficiency in NK cell activation. This suggests that the KIR2DL2 receptor creates a unique immunological environment in MS patients that favors viral persistence. Researchers hypothesize that herpesvirus reactivation, potentially through molecular mimicry mechanisms, may induce autoimmunity, tissue damage, and subsequent MS lesion development . The presence of viral infections may thus serve as a triggering factor for autoimmune responses in genetically susceptible individuals.

How does the KIR2DL2/HLA-C1 interaction influence autoimmune disease development?

The interaction between KIR2DL2 and its primary ligand HLA-C1 creates an immunological environment that may predispose individuals to autoimmune conditions. In multiple sclerosis patients, the KIR2DL2/HLA-C1 receptor-ligand pair has been associated with increased susceptibility to herpesvirus infections, which may trigger or exacerbate autoimmunity . The frequency distribution of KIR2DL2 and HLA-C1/C2 genotypes varies significantly between patients with autoimmune conditions and healthy controls. For instance, one study found that the C1/C2 HLA genotype was significantly more common in MS patients (46%) compared to healthy controls (25%) and patients with other inflammatory neurological diseases (23%), with a p-value of 9.9 × 10^-4 . This suggests that the specific combination of KIR receptors and HLA ligands shapes the NK cell repertoire and functional responses in ways that may predispose to autoimmunity.

What inflammatory markers are associated with KIR2DL2-positive multiple sclerosis patients?

KIR2DL2-positive MS patients exhibit distinct inflammatory cytokine profiles compared to both healthy controls and patients with other inflammatory neurological diseases (OIND). Studies have shown that MS and OIND patients have higher levels of several key cytokines compared to control subjects, including IL-8, IL-12p70, IL-10, and TNF-alpha . While MS and OIND patients showed similar levels of IL-8, MS patients presented notably higher IL-12p70, TNF-alpha, and IL-10 levels compared to OIND patients . This cytokine profile suggests a unique inflammatory environment in MS patients that may be influenced by KIR2DL2 expression. The elevated pro-inflammatory cytokines (IL-12p70, TNF-alpha) alongside increased anti-inflammatory IL-10 indicates a complex dysregulation of immune responses rather than simple inflammation. This cytokine signature may reflect ongoing viral-induced immune activation that contributes to autoimmune pathology in KIR2DL2-positive MS patients.

How can researchers effectively study the functional differences between KIR2DL2 and KIR2DS2?

Studying the functional differences between the inhibitory KIR2DL2 and activating KIR2DS2 receptors requires specialized approaches due to their high structural homology. An effective methodology involves:

• Initial separation of NK cell populations using flow cytometry with antibodies that recognize both receptors

• Subsequent genetic confirmation through RT-PCR specifically targeting KIR2DL2

• Cloning of NK cells to generate pure populations expressing different KIR receptor combinations

• Functional assays using target cells expressing different HLA-C ligands to assess:

  • Degranulation responses (measured by CD107a expression)

  • Cytokine production

  • Proliferative capacity

Research has shown that when KIR2DS2 and KIR2DL2 are coexpressed, NK cell inhibition via KIR2DL2 overrides NK cell activation via KIR2DS2 . Conversely, KIR2DL1 and KIR2DS2 demonstrate an additive enhancing effect on NK cell responses against C1C1 target cells . These complex interactions highlight the importance of studying receptor co-expression patterns when evaluating functional outcomes.

What experimental models are optimal for studying KIR2DL2's role in viral infections?

For studying KIR2DL2's role in viral infections, researchers should consider several complementary experimental models:

• Primary human NK cell isolation: Isolating NK cells from KIR-genotyped donors with different KIR2DL2/HLA-C combinations provides physiologically relevant material. Studies have shown that sorting KIR2DL2+ NK cells and evaluating their responses to virus-infected cells offers insights into inhibitory mechanisms .

• In vitro viral infection systems: These should include:

  • Target cells with defined HLA-C genotypes (C1/C1, C1/C2, C2/C2)

  • Viral infection models using relevant viruses (HHV-6, EBV, SARS-CoV-2, HCV)

  • Functional readouts including cytotoxicity assays, degranulation (CD107a), and cytokine production

• Humanized mouse models: These allow in vivo assessment of KIR2DL2's impact on viral clearance and persistence.

• Clinical correlation studies: Examining the relationship between KIR2DL2 genotype, viral load, and clinical outcomes in patient cohorts.

Research has demonstrated that NK cells from MS patients expressing KIR2DL2 show decreased activation against herpesvirus-infected cells compared to control subjects , highlighting the importance of studying both healthy and disease contexts. Comprehensive experimental design should include appropriate controls, such as comparing KIR2DL2+ with KIR2DL2- NK cells from the same individual when possible, and accounting for HLA-C genotype variations.

How do KIR2DL2 and KIR2DS2 cooperatively shape the NK cell repertoire?

KIR2DL2 and KIR2DS2 exert significant influence on the NK cell receptor repertoire through complex interactions with other KIR molecules and their ligands. Research shows that KIR2DL2/3/S2 NK cells predominate within the KIR repertoire in KIR2DL2/S2+ individuals, while the KIR2DL1/S1 NK cell compartment dominates in C2C2 KIR2DL2/S2- individuals . These distribution patterns suggest that the repertoire formation is influenced by the presence of both inhibitory and activating KIRs.

Studies indicate that alongside KIR2DL2, the expression of activating receptors KIR2DS1 and KIR2DS2 limits KIR2DL1 acquisition on NK cells . In KIR2DL1-negative individuals, KIR2DL2/3/2DS2 expression significantly increases compared to KIR2DL1-positive counterparts, suggesting an adjustment mechanism in repertoire formation. This challenges the notion of sequential KIR acquisition with KIR2DL1 expression following KIR2DL2/KIR2DL3, and instead supports a continuous adjustment model where KIR2D expression recalibrates according to other expressed KIR2D receptors .

What is the mechanistic basis for the differential binding affinities of KIR2DL2 and KIR2DL3 to HLA-C?

The differential binding affinities of KIR2DL2 and KIR2DL3 to HLA-C molecules stem from subtle structural differences that significantly impact receptor-ligand interactions. KIR2DL2 combines more strongly with HLA-C than KIR2DL3, enabling it to exert more powerful inhibitory effects on NK cells . While both receptors recognize HLA-C molecules of the C1 group, KIR2DL2 also demonstrates weaker affinity for C2 ligands with the N77K80 motif .

These binding differences likely result from amino acid variations in the extracellular domains that create distinct interaction surfaces. The stronger binding of KIR2DL2 may explain why KIR2DL2+ individuals show increased susceptibility to certain viral infections—the more potent inhibitory signal might prevent effective viral clearance by NK cells during early infection. Understanding these structural and functional differences requires advanced techniques such as protein crystallography, surface plasmon resonance, and molecular dynamics simulations to characterize the precise molecular interactions that govern binding affinity and functional outcomes.

What are the potential therapeutic implications of targeting the KIR2DL2/HLA-C interaction in viral infections and autoimmune diseases?

Targeting the KIR2DL2/HLA-C interaction represents a promising therapeutic strategy for both viral infections and autoimmune diseases. For viral infections like COVID-19 and HCV, where KIR2DL2 expression correlates with increased susceptibility , blocking this inhibitory receptor could enhance NK cell activity and improve viral clearance. Conversely, in autoimmune conditions like multiple sclerosis, where KIR2DL2-positive patients show increased susceptibility to herpesvirus infections that may trigger or exacerbate disease , a dual approach might be needed.

Potential therapeutic approaches include:

• Blocking antibodies: Monoclonal antibodies specifically targeting KIR2DL2 to prevent inhibitory signaling and enhance NK cell activation against viruses

• Peptide inhibitors: Small molecules designed to disrupt KIR2DL2/HLA-C1 binding

• Combined antiviral/immunomodulatory strategies: In autoimmune conditions, simultaneously targeting herpesvirus infections while modulating the KIR2DL2-mediated NK cell response

• Personalized approaches: Tailoring treatments based on individual KIR/HLA genotypes